Advanced Prostate Cancer Drug May Help at Earlier Stage

WEDNESDAY, May 16 (HealthDay News) -- A drug approved to treat advanced prostate cancer appears to help men who have localized high-risk prostate cancer if given before surgery.

Tokai Pharmaceuticals’ Galeterone Phase 1 Data in Patients with Advanced Prostate Cancer to be Presented at ASCO ...

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone , in patients with castration-resistant prostate cancer will be highlighted in a poster presentation titled, “Phase I clinical trial of galeterone , a ...

US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA

CHARLOTTE, N.C., May 17, 2012 /PRNewswire/ -- The performance of high intensity focused ultrasound (HIFU) and focal therapy to deliver minimally invasive treatment of prostate cancer is the focus of multiple ...

J&J drug shows promise in high-risk prostate cancer

(Reuters) - Adding Johnson & Johnson's advanced prostate cancer drug, Zytiga, to hormone therapy before surgery has been shown for the first time to eradicate tumors in some men with high-risk forms of the disease. The mid-stage trial found that six months of treatment with the combination therapy completely or nearly eliminated the cancer in a third of patients, all of whom had localized ...

Britain to fund prostate cancer pill in U-turn

LONDON (Reuters) - Britain's drug watchdog has reversed a controversial decision not to fund a new prostate cancer pill that was developed in the country after maker Johnson & Johnson agreed a new discount on supplies to the UK state healthcare service. Zytiga, which is known chemically as abiraterone, was approved last year in Europe and the United States to treat advanced prostate cancer in ...